Featured Research

from universities, journals, and other organizations

Chemotherapy and radiotherapy: Pioneering technique to effectively treat mucositis

Date:
February 14, 2013
Source:
University of Granada
Summary:
Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators have now patented a melatonin gel that they say is 100% effective against this inflammatory reaction.

Rat subjected to irradiation (radiotherapy).
Credit: Image courtesy of University of Granada

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that "is believed to be the first product developed anywhere in the world to combat mucositis," according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.

Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.

Radiotherapy and Mucositis

It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.

At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.

This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. "Melatonin alleviates the inflammatory reaction and protects the mitochondria, says Germaine Escames Rosa, the principal author of the study, "and for this reason we think it could be useful for treating mucositis."

The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. "The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases." Any other type of melatonin application, such as different concentrations, would not have the same effect.


Story Source:

The above story is based on materials provided by University of Granada. Note: Materials may be edited for content and length.


Cite This Page:

University of Granada. "Chemotherapy and radiotherapy: Pioneering technique to effectively treat mucositis." ScienceDaily. ScienceDaily, 14 February 2013. <www.sciencedaily.com/releases/2013/02/130214075533.htm>.
University of Granada. (2013, February 14). Chemotherapy and radiotherapy: Pioneering technique to effectively treat mucositis. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2013/02/130214075533.htm
University of Granada. "Chemotherapy and radiotherapy: Pioneering technique to effectively treat mucositis." ScienceDaily. www.sciencedaily.com/releases/2013/02/130214075533.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins